Success Metrics

Clinical Success Rate

50.0%

Based on 1 completed trials

Completion Rate

50%(1/2)

Active Trials

2(50%)

Results Posted

200%(2 trials)

Terminated

1(25%)

Phase Distribution

Ph phase_4

50%

Ph not_applicable

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 4Post-market surveillance

2(50.0%)

N/ANon-phased studies

2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(1)

Terminated(1)

Detailed Status

Recruiting1

Completed1

Terminated1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 4

Trials by Phase

Phase 42 (50.0%)

N/A2 (50.0%)

Trials by Status

recruiting125%

completed125%

terminated125%

active_not_recruiting125%

Recent Activity

2 active trials

Showing 4 of 4

active_not_recruitingphase_4

Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders

NCT05108558

recruitingphase_4

Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease

NCT06649539

completednot_applicable

Penile Length Maintenance Post-Prostatectomy

NCT03500419

terminatednot_applicable

Penile Lengthening Pre-Penile Prosthesis Implantation

NCT03500406

Clinical Trials (4)

Showing 4 of 4 trials

NCT05108558Phase 4

Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders

Active Not Recruiting

NCT06649539Phase 4

Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease

Recruiting

NCT03500419Not Applicable

Penile Length Maintenance Post-Prostatectomy

Completed

NCT03500406Not Applicable

Penile Lengthening Pre-Penile Prosthesis Implantation

Terminated

All 4 trials loaded

Drug Details

Intervention Type: DEVICE
Total Trials: 4